Company** | Company# | Type/Product Area | Terms/Details (Month) |
(Country) | (Country) | ||
Abgenix Inc. | Millennium Bio- | Research collaboration; use of | This is expansion of companies' 7/98 |
Therapeutics Inc. | Abgenix's XenoMouse technology | agreement; Millennium Bio will devel- | |
(majority-owned | to generate fully human antibodies | op, manufacture and market any | |
subsidiary of | to Millennium Bio's antigen target | products; Abgenix gets research pay- | |
Millennium Phar- | in area of inflammatory disease | ments, additional fees, milestones and | |
maceuticals Inc.) | royalties (10/98) | ||
Acacia | Aurora Biosciences | Agreement to cross-license key | Companies will settle intellectual pro- |
Biosciences Inc.* | Corp. | genomic technologies (Aurora's | perty dispute and cross-license certain |
fluorescent protein technology | elements of respective technologies; | ||
and Acadia's genome reporter | under certain conditions, companies | ||
matrix technology) | will pay each other license fees; | ||
financial terms ND (10/98) | |||
Affymetrix Inc. | Human Genome | Agreement on use of Human | This is 2nd agreement between the com- |
Sciences Inc. | Genome's human genome database | panies on use of Human Genome's data | |
sequences in Affymetrix's DNA | in GeneChips; Affymetrix gets rights to | ||
probe arrays (GeneChip) | commercialize GeneChip probe arrays | ||
based on Human Genome's human | |||
genome sequences; it will sell those | |||
arrays to Human Genome and its data- | |||
base consortium members; after 2001, | |||
Affymetrix can extend agreement to | |||
all future Human Genome database | |||
subscribers (11/98) | |||
Molecular Applica- | Collaboration to develop bioinfor- | Companies will share any profits; other | |
tions Group Inc.* | matics software tools (to couple | terms and details ND (9/98) | |
expression data from GeneChip | |||
system with information about | |||
structure and function of genes) | |||
Allergy | Ribi ImmunoChem | License on Ribi's MPL immuno- | Allergy Therapeutics will use MPL in its |
Therapeutics | Research Inc. | modulator for use in allergy | products for allergies to pollen from gras- |
Ltd.* (U.K.) | desensitization products | ses, trees and house dust mites (10/98) | |
Axis Genetics | Biomira Inc. | Research collaboration on each | Axis will manufacture and supply its |
plc* (U.K.) | (Canada) | company's cancer vaccine that targets | vaccine (produced in plants) to Bio- |
MUC-1 peptide found on common | mira for evaluation in preclinical test- | ||
solid tumors; the 2 vaccines induce | ing; each company will bear its own | ||
different types of immune responses | costs (11/98) | ||
Biogen Inc. | Genzyme Corp. | Marketing of Biogen's Avonex | Genzyme has exclusive rights to com- |
(recombinant human interferon | mercialize and distribute product in | ||
beta-1a) for treating relapsing | Japan; Genzyme responsible for clinical | ||
multiple sclerosis | development and regulatory approval | ||
in Japan; financial terms ND (9/98) | |||
BioMarin | Genzyme Corp. | Formation of joint venture on | BioMarin will get $12.1M milestone |
Pharmaceutical | BioMarin's recombinant enzyme | payment when FDA approves product | |
Inc. (subsidiary of | alpha-L-iduronidase for treating | for sale; Genzyme bought $8M in Bio- | |
Glyko Biomedical | lysosomal storage disorder muco- | Marin equity (for 5.6% stake) and will | |
Ltd.; TSE:GBL, | polysaccharidosis I (pivotal clinical | buy another $10M in stock in private | |
Canada) | trial initiated 1/98) | placement concurrent with BioMarin's | |
IPO at price to public (letter of intent | |||
6/98; finalized 9/98) | |||
Biomira Inc. | Biovector Thera- | Agreement to co-develop Biomira's | Biovector will market product in North |
(Canada) | peutics SA* | liposomal idiotypic vaccine for | America and manufacture and market it |
(France) | B-cell lymphoma (consists of | outside North America; Biomira retains | |
patient-specific tumor antigen | North American manufacturing rights; | ||
combined with interleukin-2 | Biomira gets up-front fee of $0.5M, | ||
and lipids) | milestones of $15.5M, plus royalties; | ||
Biomira also gets transfer fees for cost | |||
of goods; Biovector will provide most | |||
of funding for clinical trials (9/98) | |||
BioNative AB* | Maxim Pharma- | Collaboration to test Maxamine | ND (9/98) |
(Sweden) | ceuticals Inc. | (immunomodulator) in combination | |
with BioNative's natural interferon | |||
(Interferon Alfanative) and inter- | |||
leukin-2 in European Phase II | |||
clinical trial in renal cell carcinoma | |||
BioStar Inc.* | Agouron Pharma- | Agreement to develop point-of- | ND (10/98) |
ceuticals Inc. | care diagnostic test (via BioStar's | ||
optical immunoassay technology) | |||
to assist in clinical development | |||
of Agouron's rhinovirus drug | |||
candidate AG7088 | |||
Chiron Corp. | MedImmune Inc. | Research collaboration; use of Chi- | Chiron gets up-front payment, milestones |
ron's MF59 vaccine adjuvant with 2 | and royalties; further details ND (9/98) | ||
of MedImmune's vaccines (against | |||
parvovirus B19 [for various indica- | |||
tions, including anemia in AIDS | |||
and cancer]; and against Escherichia | |||
coli [for urinary tract infections]) | |||
Collagenesis | Osiris Thera- | Research collaboration; evaluation | ND (9/98) |
Inc.* | peutics Inc.* | of Collagenesis' collagen-based | |
tissue matrix delivery system for | |||
use in delivery of Osiris' | |||
mesenchymal stem cells for soft- | |||
tissue regeneration (especially | |||
tendons and ligaments) | |||
CpG Immuno- | Isis Pharma- | License agreement on Isis' patents | CpG gets exclusive worldwide rights to |
Pharmaceuticals | ceuticals Inc. | covering immune stimulation by | methods and applications covered by |
Inc.* | phosphorothioate oligonucleotides | patents (not including claims for anti- | |
sense therapies); Isis gets license fee | |||
and part of sublicensing revenues; Isis | |||
will purchase "meaningful" equity stake | |||
in CpG (8/98) | |||
Creative | Biogen Inc. | Restructuring of 12/96 collaboration | This program is taking longer than |
Bio-Molecules Inc. | on use of Creative's morphogenic | anticipated; Biogen is reducing its role; | |
protein OP-1 for treating both acute | Creative will assume primary role in | ||
and chronic kidney failure | developing therapy in the chronic | ||
disease setting, for which Biogen will | |||
provide $4.75M in research support; | |||
Biogen retains option through 1999 to | |||
resume product development in chronic | |||
disease setting; Creative will also | |||
assume all rights to develop product in | |||
acute disease setting, independent of | |||
Biogen (10/98) | |||
CV Therapeutics | Incyte Pharma- | Joint research collaboration to | Incyte will own any data produced; CV |
Inc. | ceuticals Inc. | develop prototype gene expression | Therapeutics gets perpetual, nonexclu- |
database in cardiovascular biology | sive license to use data in its internal | ||
(especially atherosclerosis and | R&D; CV Therapeutics will develop | ||
restenosis) | biological models of targeted disease | ||
states and supply mRNA samples to | |||
Incyte, which will generate microarray- | |||
based expression data (9/98) | |||
Cytogen Corp. | Elan Corp. plc | Unwinding of Targon Corp. joint | Cytogen retains assets it originally con- |
(Ireland) | venture (formed in 9/96) | tributed to Targon; Elan will pay Cyto- | |
gen $4M cash ($2M of which represents | |||
new convertible note issued to Elan, | |||
which Elan has option of converting | |||
into Cytogen common stock at $2.80 | |||
per share); Elan will acquire complete | |||
ownership of Targon and all remaining | |||
assets, including opioid analgesic pro- | |||
duct Morphelan; existing $10M note | |||
from Cytogen to Elan relating to license | |||
on Morphelan is cancelled (8/98) | |||
Electropharma- | Elan Corp. plc | Research and license agreement; | Electropharmacology gets worldwide |
cology Inc. (OTC | (Ireland) | development of Elan's flexible | rights to therapeutic applications of |
Bulletin Board: | iontophoretic patch technology for | improved PEMS product as well as | |
EPHI) | non-cosmetic dermatology and | combined PEMS/iontophoretic prod- | |
wound care applications; also, | ucts; Elan gets up-front payment, | ||
development of flexible patch | license fees and royalties; Elan bought | ||
version of Electropharmacology's | $7.5M in Electropharmacology con- | ||
pulsed electromagnetic signal | vertible preferred shares and warrants; | ||
(PEMS) technology | Elan may buy additional $2M in com- | ||
mon stock (letter of intent 8/98; final- | |||
ized 10/98) | |||
Endorex Corp. | Elan Corp. plc | Formation of joint venture, named | Companies announced formation of |
Innovax Corp., to develop oral | joint venture in 1/98; finalized 8/98; | ||
vaccines via Endorex's Orasome | Innovax owned 80.1% by Endorex and | ||
oral drug delivery technology | 19.9% by Elan; each partner will pro- | ||
(especially to reformulate injectable | vide personnel; combined total funding | ||
vaccines developed by big pharma) | of $3M for 1st year (8/98) | ||
Elan Corp. plc | Formation of 2nd joint venture to | Companies contributed total $10.5M to | |
commercialize products using Elan's | joint venture, which is 80.1% owned by | ||
Medipad drug delivery system | Endorex and 19.9% by Elan; Elan | ||
(disposable system that combines | bought $8.4M in Endorex preferred | ||
patch and infusion pump) for 2 | stock (exchangeable for stock in joint | ||
undisclosed drugs | venture or Endorex common stock at | ||
premium to market); joint venture gets | |||
exclusive worldwide rights to Medipad | |||
for use with specific drugs; Elan gets | |||
$10M license fee from joint venture as | |||
well as milestones and royalties (10/98) | |||
EnzyMed Inc.* | RiboGene Inc. | Joint collaboration on drugs for in- | Parties will jointly own and develop any |
fectious diseases; use of RiboGene's | compounds resulting from research | ||
infectious disease high-throughput | (8/98) | ||
assays to screen EnzyMed's small- | |||
molecule chemical libraries | |||
Genetica Inc.* | Osiris Thera- | Research collaboration on functional | Osiris gets exclusive worldwide rights |
peutics Inc.* | genomics of human mesenchymal | to therapeutic agents and drug targets; | |
stem cells; focus on discovery of | Genetica gets royalties (10/98) | ||
genes that control growth and | |||
differentiation of these cells | |||
ImmGenics | Corixa Corp. | Research collaboration on antibody- | ImmGenics gets R&D payments, mile- |
Pharmaceuticals | based immunotherapeutics and | stones and royalties; Corixa bought | |
Inc.* (Canada) | diagnostics; use of ImmGenics' | $1.75M in ImmGenics preferred stock | |
selected lymphocyte antibody tech- | and may invest another $1.25M in 1999 | ||
nology to develop antibodies to | (11/98) | ||
Corixa's antigens in cancer and | |||
infectious disease | |||
Immunotech SA | The Medicines Co.* | License agreement on Immunotech's | The Medicines Co. acquired exclusive |
(France; wholly | drug IS-159 (highly selective 5- | worldwide rights to drug; further terms | |
owned subsidiary | hydroxytriptamine [5-HT] receptor | ND (8/98) | |
of Beckman Coulter | agonist) for treating acute migraines | ||
Inc.; NYSE:BEC) | (Phase II European trials completed) | ||
Introgen | LXR Biotechnology | Evaluation and option agreement; | Introgen will assess antitumor activity |
Therapeutics | Inc. | integration of LXR's Bak gene | of Bak gene; Introgen gets option on |
Inc.* | (induces apoptosis and is down- | exclusive license to gene; LXR gets | |
regulated in various tumors) into | up-front payment for option; if exer- | ||
Introgen's gene therapy technology | cised, LXR gets milestones and royal- | ||
ties (10/98) | |||
Ligand | Elan Corp. plc | Strategic alliance and license on | Ligand will pay Elan for product rights |
Pharmaceuticals | (Ireland) | Elan's once-daily solid oral dosage | (up-front license fees and milestones in |
Inc. | form of morphine (Morphelan) for | cash or Ligand stock); companies have | |
use in treating pain associated with | certain co-promotion rights in U.S., | ||
cancer and AIDS (in Phase III trials) | Canada and Europe; Elan bought $20M | ||
in Ligand stock ($14.9M for 1.3M | |||
shares on 9/30/98 and $5.1M for | |||
0.44M shares on 11/9/98); Elan will also | |||
buy $110M in Ligand's zero coupon | |||
convertible senior notes due 2008 (it | |||
bought the 1st $30M in notes on 11/9/98 | |||
and will buy $80M more prior to | |||
12/31/99); the interest-bearing notes are | |||
convertible into Ligand common stock | |||
at $14.00 per share; Elan owns 8% of | |||
Ligand after close of $20M equity | |||
purchase and initial note takedown | |||
(letter of intent 9/98; finalized 11/98) | |||
The Liposome | Amgen Inc. | Marketing of Liposome Co.'s | Amgen will market product in Aus- |
Co. Inc. | Abelcet (amphotericin B lipid | tralia and New Zealand; further details | |
complex) for 1st-line therapy | ND (10/98) | ||
of invasive fungal disease | |||
Medarex Inc. | Centocor Inc. | License agreement on fully human | Centocor exercised option from 10/97 |
antibodies to 4 antigens created | agreement; Centocor gets exclusive | ||
with Medarex's HuMAb-Mouse | license to antibodies; Centocor paid | ||
technology | $4M for 0.9M Medarex shares (10/98) | ||
Molecular | Clontech | Joint development and marketing of | Microarrays will be made broadly avail- |
Dynamics Inc. | Laboratories Inc.* | prefabricated cDNA expression | able to research community; early ver- |
(subsidiary of Amer- | microarrays (for high-throughput | sions will be available to participants in | |
sham Pharmacia | R&D) | Molecular Dynamics' microarray tech- | |
Biotech Inc.) | nology access program (9/98) | ||
MorphoSys AG* | LeukoSite Inc. | Research collaboration on therapeutic | 2-year collaboration; LeukoSite gets |
(Germany) | monoclonal antibodies for inflamma- | exclusive worldwide rights to any anti- | |
tory and autoimmune disorders; use | body therapeutics that arise; MorphoSys | ||
of MorphoSys' human combinatorial | gets up-front fee, milestones and royal- | ||
antibody library to screen 3 of Leuko- | ties (8/98) | ||
Site's disease targets (chemokine | |||
receptors and integrins) | |||
NeoGenesis | Epix Medical Inc. | Collaboration on advanced contrast | ND (10/98) |
Pharmaceuticals | agents for magnetic resonance | ||
Inc.* | imaging; Epix will screen Neo- | ||
Genesis' NeoMorph combina- | |||
torial chemistry libraries for | |||
product candidates | |||
Novalon | Millennium Pharma- | Evaluation and research agreement; | 1-year agreement; Millennium will |
Pharmaceutical | ceuticals Inc. | Novalon will identify BioKeys | conduct all drug candidate screening; |
Corp.* | (surrogate ligands that bind | Novalon gets license fees, research | |
specifically to functional domains of | funds, milestones and royalties (11/98) | ||
target proteins) for limited number | |||
of Millennium's genomic targets | |||
Paracel Inc.* | Celera Genomics | Collaboration to develop high- | Paracel will install its GeneMatcher |
Corp. (unit of The | resolution informatics tools to | high-performance genetic data analysis | |
Perkin-Elmer Corp.; | analyze genomic information; | system at Celera (GeneMatcher is a | |
NYSE:PKN) | focus on expressed sequence tags | massively parallel genomic data analysis | |
(DNA- and protein-level com- | engine); further details ND (9/98) | ||
parisons of sequence data) | |||
Pharming Group | Genzyme Corp. | Formation of joint venture on | Genzyme made $14M equity invest- |
NV (EASDAQ: | enzyme human alpha-glucosidase | ment in Pharming in 7/98; Genzyme | |
PHAR; the | for treating Pompe's disease | will fund $14M in development costs; | |
Netherlands) | (lysosomal storage disease); prod- | above that amount, companies will | |
uct produced in milk of trans- | equally fund development costs; | ||
genic rabbits | Pharming gets $7M milestone on FDA | ||
approval of product for sale (letter of | |||
intent 7/98; finalized 10/98) | |||
Protein Design | Genentech Inc. | Cross-licensing agreement on mono- | Companies granted each other rights to |
Labs Inc. | clonal antibody patents | license particular antibodies; Genentech | |
will pay $6M up-front fee to Protein | |||
Design for rights to license up to 6 | |||
antibodies; Protein Design will pay $1M | |||
up-front fee to Genentech for same con- | |||
sideration; each company can obtain | |||
nonexclusive, royalty-bearing licenses | |||
under other's patents upon payment of | |||
$1M fee per antibody (9/98) | |||
Genentech Inc. | License under Protein Design's | Genentech gets nonexclusive license, | |
antibody humanization patents | issued under terms of 9/98 agreement | ||
for antibodies to HER2 antigen, | (see above); Genentech paid $1M | ||
including Herceptin (FDA- | license fee; Protein Design gets | ||
approved 9/98) | royalties (11/98) | ||
Rapigene Inc. | Gemini Research | Research collaboration; use of | Gemini will identify single nucleotide |
(subsidiary of | Ltd.* (U.K.) | Gemini's Phenobase database | polymorphisms (SNPs) from genes |
Chiroscience Group | and Rapigene's DNA analysis | selected as relevant to obesity; Rapi- | |
plc., U.K.) | technologies to discover genes | gene will develop and perform geno- | |
for obesity | typing assays on twins from Gemini's | ||
clinical database; each company will | |||
bear own costs; any intellectual pro- | |||
perty will be licensed to 3rd parties | |||
for therapeutic and diagnostic applica- | |||
tions; companies will share income (9/98) | |||
RiboTargets Ltd.* | Molecular Simula- | Collaboration to develop software | 3-year collaboration; details ND (10/98) |
(U.K.) | tions Inc. (subsidiary | specific to modeling of RNA targets | |
of Pharmacopeia Inc.) | and design of RNA-targeted drugs | ||
Roslin Bio-Med | Kimeragen Inc.* | Collaboration to develop methods | Goal is to create animal organs that can |
Inc.* (Scotland) | for precise genetic modification of | be transplanted into humans; details ND | |
livestock; use of Kimeragen's | (10/98) | ||
chimeraplasty technology to | |||
modify 2 genes (ovine PRP [gene | |||
associated with scrapie] and | |||
ovine alpha 1-3 gal [associated | |||
with transplant rejection of | |||
animal organs by humans]) | |||
Sangamo Bio- | Millennium Pharma- | Target validation collaboration; | Millennium will evaluate use of Gene |
Sciences Inc.* | ceuticals Inc. | use of Sangamo's Universal | Tools in its discovery research; San- |
GeneTools (rationally designed | gamo gets funding; details ND (10/98) | ||
zinc finger DNA recognition proteins | |||
that selectively recognize and | |||
regulate any target gene or DNA | |||
sequence) to validate gene | |||
targets for drug discovery | |||
SkyePharma plc | Sepracor Inc. | Joint development program; use | SkyePharma will develop product |
(U.K.) | of SkyePharma's metered-dose | formulation, scale-up production and | |
aerosol technology to deliver | supply clinical trial materials; Sepracor | ||
Sepracor's chiral versions of | retains commercial manufacturing | ||
widely used drugs for asthma | rights; Sepracor will sell products under | ||
exclusive worldwide license from | |||
SkyePharma; Sepracor will fund Skye- | |||
Pharma's development costs; SkyePhar- | |||
ma gets milestones and royalties (10/98) | |||
Sunol Molecular | Anergen Inc. | License agreement on Sunol's | Anergen will evaluate Sunol's mole- |
Corp.* | single-chain, recombinant forms of | cules for potential use in its AnergiX- | |
major histocompatibility complex | based program for multiple sclerosis | ||
class II (MHC-II) molecules, | therapies; license is result of 1997 | ||
coupled with anti-angiogenic peptide | research collaboration between the | ||
companies (9/98) | |||
Systems | Cor Therapeutics | Combinatorial chemistry consortium | SIDDCO will integrate its combinator- |
Integration Drug | Inc. | agreement; Cor will work with SIDDCO | ial and medicinal chemistry technology |
Discovery Co. | and other consortium partners to build | into Cor's drug discovery programs; | |
(SIDDCO)* | broad-based combinatorial chemistry | Cor will provide research funds and gets | |
technology platform | access to technology on royalty-free | ||
basis (8/98) | |||
Tanox | ProCyte Corp. | Expansion of 5/98 agreement on | Tanox will now distribute products in |
Biosystems Inc.* | ProCyte's wound-care products | Singapore, Thailand, Malaysia, the | |
Iamin Gel and OsmoCyte | Philippines and Indonesia (as well as | ||
pillow dressings | People's Republic of China, Hong Kong | ||
and Taiwan) (9/98) | |||
Trega | Biogen Inc. | Supply agreement on Trega's | 2-year, nonexclusive agreement; Trega |
Biosciences Inc. | Chem.Folio (small-molecule | will suppy Chem.Folio libraries to Bio- | |
combinatorial libraries) | gen; Biogen also gets nonexclusive | ||
worldwide licenses to certain of Trega's | |||
chemical synthesis technologies; Trega | |||
gets guaranteed funding of $7.5M over | |||
2 years, plus milestones (10/98) | |||
Vanguard Medica | Elan Corp. plc | License agreement on Vanguard's | Elan gets exclusive rights in North |
Group plc (U.K.) | (Ireland) | anti-migraine therapy frovatriptan | America to sell and distribute product; |
(5HT1B/1D agonist; Phase III | Elan will buy $10M in Vanguard stock | ||
trials completed) | (at $6.25 per share) for a 3% stake; | ||
Vanguard also gets $50M in mile- | |||
stones, plus royalties; transaction sub- | |||
ject to government approvals (10/98) | |||
Xenometrix Inc. | Affymetrix Inc. | License agreement on Xenometrix's | Affymetrix gets nonexclusive license; |
(OTC Bulletin | gene expression profiling; covers | companies will also collaborate on | |
Board:XENO) | collection of gene expression profiles | development and design of DNA | |
using all methods, including high- | arrays for toxicology applications | ||
density microarrays | (10/98) | ||
Gene Logic Inc. | License agreement on Xenometrix's | Gene Logic gets nonexclusive license; | |
gene expression profiling; covers | further details ND (10/98) | ||
collection of gene expression profiles | |||
using all methods, including high- | |||
density microarrays | |||
Xoma Corp. | Diagnostic | License agreement; use of Xoma's | Diagnostic Products licensed technol- |
Products Corp. | lipopolysaccharide binding protein | ogy; Xoma gets royalties (8/98) | |
(biochemical marker of systemic | |||
exposure to bacterial endotoxin) in | |||
diagnostic tests for diseases asso- | |||
ciated with bacterial endotoxin | |||
NOTES: | |||
@ This chart covers biotech company deals with other biotech companies announced between 8/1/98 and 11/13/98. | |||
ND = Not disclosed, reported and/or available; TSE= Toronto Stock Exchange | |||
# Indicates funding partner, where applicable. | |||
* Private companies are indicated with an asterisk. | |||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found be referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 12-13. |